Innovation in treatment

The site follows what changes how long and how well people live, and treatment is the part of that which arrives on a date. A drug is approved; an operation is first performed; a device is licensed. What follows is slower and less reported: whether it is paid for, whether it reaches beyond the centres that trialled it, and whether the effect in the trial survives contact with the population that gets it.

That gap is the reason this driver is not simply the sum of the disease pages. Transportability analysis is beginning to put numbers on it — the same liraglutide trial carried onto a US veteran population produced a three-year benefit nearly three times the trial's own, while a transcatheter valve trial carried onto the Dutch registry produced one substantially smaller. A treatment's effect is not a property of the treatment alone.

The evidentiary route is changing too, and faster than the treatments. Biosimilars are now approved on analytical and pharmacokinetic equivalence without a comparative efficacy trial, which is how cheaper versions of expensive biologics arrive. Cost-effectiveness at launch is calculated from trial data and a model, and almost never revisited once real use begins. Surgical and procedural innovation, by contrast, has no approval step at all: an operation enters practice through adoption, and the evidence, when it comes, usually comes afterwards.

Status

building

Direction

strengthening

Would change our view

A comparison of launch-time cost-effectiveness estimates against what treatments turned out to cost and deliver. Evidence that a novel mechanism moved a population mortality rate rather than a trial endpoint. A regulator requiring evidence for a surgical innovation comparable to that required for a drug. Routine publication of transported effect estimates alongside trial results.

Trackers

Gaps

Any systematic record of surgical and procedural innovation comparable to drug approval registers. Access and uptake data outside high-income countries. What happens to a treatment's measured effect between the trial and the tenth year of use.